Keywords: Biogen Idec, BG-12, Multiple sclerosis, Dimethyl fumarate

Positive Ph III data for Biogen Idec's oral MS drug candidate BG-12

Article | 25 April 2012

Print This

US biotech firm Biogen Idec (Nasdaq: BIIB) says that detailed positive data from CONFIRM, the second Phase III clinical trial ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in